๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 18 Guangzhou 14 Shanghai 8 Hefei 7 Bengbu 6
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing18 Guangzhou14 Shanghai8 Hefei7 Bengbu6
All 40 locations
Target enrolment
to

Trials with a site in Beijing

18 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
SMP-656 for HER2-Positive Advanced Breast Cancer
NCT07726342HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
Chengdu SciMount Pharmatech Co., Ltd.
Phase 2
60
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Nanjing
2026-07-16
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939HER2-positive Breast Cancer
Hoffmann-La Roche
Phase 2/3
650
Nanjing, Shanghai, Beijing, Bengbu, Chengdu, Fuzhou, Guangzhou, HangzhouZhejiang
2026-05-21
Recruiting
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
NCT07377643HER2-positive Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 3
540
Beijing
2026-02-10
Recruiting
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT07043725HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
544
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou
2025-09-15
Recruiting
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029HER2-positive Breast Cancer
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 3
228
Bengbu, Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou
2025-01-10
Recruiting
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
NCT06958627HER2 Positive Breast Cancer, Pyrotinib Treatment
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
964
Beijing
2024-04-30
Active, closed
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
NCT06265428HER2-positive Breast Cancer
DualityBio Inc.
Phase 3
228
Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou
2024-01-29
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer
Daiichi Sankyo
Observational
800
Beijing, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou
2024-01-15
Recruiting
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
NCT06035016HER2-positive Breast Cancer, Early-stage Breast Cancer
Peking Union Medical College Hospital
Observational
300
Beijing
2023-06-01
Active, closed
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjetaยฎ in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
DrugHLX11
Shanghai Henlius Biotech
Phase 3
900
Bengbu, Hefei, Lu'an, Maโ€™anshan, Wuhu, Beijing, Chongqing, Chongqi
2022-04-25
Recruiting
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
NCT04481932HER2-positive Breast Cancer
Peking University
Phase 2
104
Beijing
2020-07
Recruiting
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
NCT06693024HER2-positive Breast Cancer
Shu Wang
Observational
2,806
Beijing
2019-01-01
Recruiting
Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
NCT06722599HER2-positive Breast Cancer
Shu Wang
Observational
171
Beijing
2019-01-01
Recruiting
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
NCT06711068HER2-positive Breast Cancer
Shu Wang
Observational
8,077
Beijing
2019-01-01
Recruiting
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
NCT06722612HER2-positive Breast Cancer
Shu Wang
Observational
2,916
Beijing
2019-01-01
Recruiting
Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
NCT06693037HER2-positive Breast Cancer
Shu Wang
Observational
2,092
Beijing
2019-01-01
Recruiting
De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
NCT06700369HER2-positive Breast Cancer
Shu Wang
Observational
519
Beijing
2015-01-01
Recruiting
Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
NCT06711055HER2-positive Breast Cancer
Shu Wang
Observational
285
Beijing
2015-01-01
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

15 of the 18 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 18 studies
PhaseStudiesRecruitingShare
Observational9950%
Phase 35327.8%
Phase 22111.1%
Phase 2/32211.1%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Shu Wang77
Cancer Institute and Hospital, Chinese Academy of Medical Sciences11
Chengdu SciMount Pharmatech Co., Ltd.10
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.11
Daiichi Sankyo11
DualityBio Inc.10
GeneQuantum Healthcare (Suzhou) Co., Ltd.11
Hoffmann-La Roche11
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.11
Peking Union Medical College Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.